Alicyn Campbell

As Head of Digital Health across all of Oncology R&D at AstraZeneca, my focus is on leveraging emerging technology to improve patient care and expand the evidence base for oncology treatments. I have deep experience in developing and implementing innovative patient relevant evidence strategies across tumour types within oncology drug development and rare disease.

I believe that reliable empirical evidence is the backbone of empowered decision- making. I’m most passionate about measuring the impact of cancer, and the tolerability of anti-cancer therapies, on patients in a rigorous and reliable way. This work is critical in providing patients with the best evidence to make important healthcare decisions, such as treatment choice, following a cancer diagnosis.

As founder of the strategic advising group, Patient Relevant Evidence, I work to optimize patient-centric evidence generation for non-profit advocacy entities and academic consortiums. This includes recent work with the European organisation for the Treatment of cancer focused on the development of international standards in analysing patient-reported outcomes and quality of life endpoints for cancer clinical trials for regulatory evaluation.

Most recently, I led Roche/Genentech’s oncology patient-centred outcomes research group, in which I was responsible for novel Food and Drug Administration (FDA) patient-reported outcomes labelling claims on products for lymphoma and haemophilia. Additionally, I developed the Symptoms in Lung Cancer tool while at Roche which was included in multiple front-line Phase 3 registration trials. Prior to that, I was a Director in Health Economics and Outcomes Research at Pfizer Oncology responsible for outcomes research strategy for the development pipeline.

Over the course of my career, I have been a contributor and advisor to numerous policy initiatives such as the landmark 21^st Century Cures legislation. I’ve participated in various FDA workshops and legislative briefings about the importance of the patient experience in drug development. I also served as co-chair of the Critical Path Institute’s Non-Small Cell Lung Cancer Working Group. My work has been recognised by Former Vice President Biden’s Cancer Moonshot Initiative.

I completed my Masters of Public Health from the University of Connecticut School of Medicine with concentrations in Epidemiology and Outcomes Research.